Flumatinib (HH-GV-678) is a novel inhibitor of Bcr-Abl with IC50 values of 1.2 nM, 307.6 nM and 665.5 nM for c-Abl, PDGFRβand c-Kit, respectively.
research use only
Cat.No.S9973
| Related Targets | EGFR VEGFR JAK FGFR PDGFR Src HIF FLT3 HER2 FLT |
|---|---|
| Other Bcr-Abl Inhibitors | Degrasyn (WP1130) Bafetinib (INNO-406) Rebastinib (DCC-2036) GNF-5 Berbamine GNF-2 Olverembatinib dimesylate (GZD824) PD173955 GNF-7 Berbamine dihydrochloride |
|
In vitro |
DMSO
: 100 mg/mL
(177.74 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 562.59 | Formula | C29H29F3N8O |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 895519-90-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | HH-GV678 | SMILES | CN1CCN(CC1)CC2=CC=C(C=C2C(F)(F)F)C(=O)NC3=CN=C(C)C(=C3)NC4=NC(=CC=N4)C5=CN=CC=C5 | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
c-Abl
1.2 nM
PDGFRβ
307.6 nM
c-Kit
665.5 nM
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2022-05-10)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05367765 | NOT_YET_RECRUITING | CML, Chronic Phase |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2022-04-30 | PHASE4 |
| NCT06530810 | NOT_YET_RECRUITING | Chronic Myelogenous Leukemia; CML Chronic Phase; CML Accelerated Phase |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2024-07-31 | PHASE1 |
| NCT05433532 | COMPLETED | Philadelphia Chromosome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Mixed Phenotype Acute Leukemia |
The First Affiliated Hospital of Soochow University |
2022-05-01 | PHASE2 |
| NCT04677439 | UNKNOWN | Flumatinib; Chronic Myeloid Leukemia, Chronic Phase; Imatinib |
Shenzhen Second People's Hospital |
2021-01-01 | PHASE4 |
| NCT04933526 | UNKNOWN | Chronic Myeloid Leukemia in Chronic Phase |
Shenzhen Second People's Hospital |
2021-07-01 | PHASE4 |
| NCT05071482 | TERMINATED | Acute Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2021-09-16 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.